Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06816927
Title Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)
Acronym GIANT
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Duke University
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.